fluoxetine has been researched along with sr141716 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Malone, DT; Taylor, DA | 1 |
| Griebel, G; Scatton, B; Stemmelin, J | 1 |
| Ben-Shabat, S; Fride, E; Gobshtis, N | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Ciccocioppo, R; Cifani, C; Di Francesco, C; Massi, M; Melotto, S; Righetti, C; Tessari, M; Zanoncelli, A | 1 |
1 review(s) available for fluoxetine and sr141716
| Article | Year |
|---|---|
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
7 other study(ies) available for fluoxetine and sr141716
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.
Topics: Animals; Consciousness; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dronabinol; Fluoxetine; Male; Microdialysis; Perfusion; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 1999 |
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
Topics: Aggression; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Diazepam; Dose-Response Relationship, Drug; Electroshock; Emotions; Fluoxetine; Gerbillinae; Immobility Response, Tonic; Male; Maze Learning; Mice; Models, Animal; Neuropsychological Tests; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Desipramine; Female; Fluoxetine; Maze Learning; Mice; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Swimming; Time Factors; Weight Gain | 2007 |
Pre-exposure to environmental cues predictive of food availability elicits hypothalamic-pituitary-adrenal axis activation and increases operant responding for food in female rats.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Conditioning, Operant; Corticosterone; Cues; Cyclobutanes; Environment; Feeding Behavior; Female; Fluoxetine; Fructose; Humans; Hypothalamo-Hypophyseal System; Motivation; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rats; Reproducibility of Results; Rimonabant; Selective Serotonin Reuptake Inhibitors; Topiramate | 2009 |